Clinical trial
A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
NCT02606214 is registered in ClinicalTrials.gov with Global Alliance for TB Drug Development as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
- Lead sponsor
- Global Alliance for TB Drug Development
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- November 30, 2015
- Completion date
- December 31, 2016
- Enrollment
- 18 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.